Physician profile
Gary R Goldstein
NPI 1952392110
$12,792.72
in general payments reported to CMS, 2019-2025
46 companies · $1,923 in 2025
The $1,923 reported for 2025 was more than what 75% of Pulmonary Disease providers received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,056 · 2020: $1,248 · 2021: $1,426 · 2022: $1,338 · 2023: $2,199 · 2024: $2,603 · 2025: $1,923.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,083 · Travel and Lodging: $642.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,082.95 |
| Travel and Lodging | $642.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $3,003.52 | 2019-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Astrazeneca Pharmaceuticals LP | $1,618.28 | 2019-2025 | Fasenra, Tezspire, Airsupra |
| Inspire Medical Systems, INC. | $1,455.22 | 2023-2025 | Inspire |
| Jazz Pharmaceuticals INC. | $1,323.11 | 2019-2025 | Xywav |
| Grifols USA, LLC | $651.85 | 2019-2025 | Prolastin-C Liquid |
| Genzyme Corporation | $590.33 | 2019-2025 | |
| Harmony Biosciences LLC | $553.67 | 2021-2025 | Wakix |
| Boehringer Ingelheim Pharmaceuticals, INC. | $505.26 | 2019-2025 | Ofev, Jascayd |
| Novartis Pharmaceuticals Corporation | $371.30 | 2019-2024 | |
| Genentech USA, INC. | $300.66 | 2019-2025 | Xolair |
| Mylan Specialty L.P. | $230.86 | 2019-2024 | Yupelri |
| Sunovion Pharmaceuticals INC. | $187.98 | 2019-2020 | |
| Itamar Medical INC | $150.40 | 2024 | Watchpatone |
| Amgen INC. | $129.86 | 2022-2024 | Tezspire |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $125.00 | 2023 | Xifaxan |
Show all 46 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Axsome Therapeutics, INC. | $120.81 | 2023-2025 | Sunosi |
| Verona Pharma, INC. | $116.49 | 2025 | Ohtuvayre |
| Resmed Corp | $109.02 | 2019-2023 | |
| Philips North America LLC | $100.98 | 2019-2025 | Vest Therapy Und, (8874) Incourage |
| Electromed, INC. | $97.46 | 2019-2021 | |
| Insmed, INC. | $90.90 | 2023-2025 | Arikayce, Brinsupri |
| Actelion Pharmaceuticals US, INC. | $89.63 | 2019-2022 | |
| Avadel Cns Pharmaceuticals, LLC | $82.43 | 2024-2025 | Lumryz |
| United Therapeutics Corporation | $82.07 | 2020-2024 | Tyvaso |
| Teva Pharmaceuticals USA, INC. | $76.93 | 2019-2023 | |
| Vanda Pharmaceuticals INC. | $62.34 | 2020-2021 | |
| Merck Sharp & Dohme LLC | $56.17 | 2019-2023 | Zerbaxa |
| Baxter Healthcare | $51.77 | 2022-2025 | Hillrom - Vest System Model 105 Home Care |
| Pfizer INC. | $50.46 | 2019-2022 | |
| Regeneron Healthcare Solutions, INC. | $39.76 | 2020-2022 | |
| Abbvie INC. | $36.26 | 2023 | |
| Bayer Healthcare Pharmaceuticals INC. | $35.97 | 2020-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $35.16 | 2020-2024 | Glassia |
| Apria Healthcare LLC | $33.78 | 2021 | |
| Csl Behring | $30.85 | 2019 | |
| Fisher & Paykel Healthcare INC | $29.96 | 2025 | Fisher & Paykel Healthcare |
| Gilead Sciences, INC. | $20.95 | 2021 | |
| Biogen, INC. | $19.77 | 2023 | Spinraza |
| Vifor Pharma, INC. | $18.20 | 2025 | Zemaira |
| Eisai INC. | $17.39 | 2021 | |
| Currax Pharmaceuticals LLC | $16.85 | 2021 | |
| Pulmonx Corporation | $16.10 | 2021 | |
| Cranial Technologies, INC | $15.44 | 2025 | Doc Band |
| Azurity Pharmaceuticals, INC. | $15.16 | 2025 | Alvesco |
| Circassia INC. | $14.81 | 2020 | |
| Cumberland Pharmaceuticals, INC. | $11.55 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gary Goldstein listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.